AdaptHealth's Painful Portfolio Pivot: The Capitated Contract Crunch

As AHCO resets guidance and sheds noncore assets, the strategic bet on capitation collides with execution reality.

AHCO · Earnings Call · 2026-08-04

The Day the Music Stopped

AdaptHealth reported a messy Q2 2026, and the market responded the way it often does to a reset: AHCO fell more than 50% in the last 90 trading days, extending a drawdown that now sits -86% from its 2021 peak. The company slashed full-year EBITDA guidance by roughly $150 million, announced the sale of its Diabetes Health business for $235 million, contributed its direct-to-consumer CPAP Shop into a joint venture, and exited several noncore Wellness-at-Home lines. The headline was a 16% organic growth quarter with record volume gains—but the margin story turned violent. “Order volumes are running higher than expected, primarily in sleep resupply and enteral products” — Suzanne Foster, Chief Executive Officer · 2026-08-04, Suzanne Foster told investors, before detailing why the West Coast capitated agreement was bleeding cash. Operating margin swung to -2.5% in Q1 2026, down 6 points from a year earlier, and negative operating income of -$20M confirms the cost structure is out of kilter. The company is now forecasting full-year adjusted EBITDA of $490–$520M (from $680–$730M), with West Coast contract headwinds accounting for $55M of the cut.

The Capitated Conundrum

The core of the problem is a ramp the company can't quite control. Suzanne described two buckets in the Q&A: excessive order volume (particularly sleep resupply and enteral) and inherited workflow inefficiencies like the overuse of urgent orders.

There's no data in the world or diligence that we could have done that us and our partner knew about that could have predicted some of these inherited messy workflows. And so from day 1, it kind of sent our operations into a bit of a tail spin because we were not expecting the level of the example, I gave urgent orders being the biggest one.
Suzanne Foster, Chief Executive Officer · 2026-08-04

This marks a sharp reversal from the confident tone just one quarter ago. In May, CFO Jason Clemens projected an EBITDA margin near 19% on "a full quarter of revenue from the new capitated arrangement" and promised the fixed costs were already in the P&L. “So that translates to a little over $160 million of EBITDA for the second quarter... Firstly, we will have an entire quarter of revenue from the new capitated arrangement, very different from Q1.” — Jason Clemens, Chief Financial Officer · 2026-05-05 Now the same contract is expected to deliver "sequential improvement over the next several quarters, reaching run rate profitability next year." The miss in Q2 alone was $15M, and management sees another $40M of drag in H2. The halo effect—the ability to layer fee-for-service business onto the new footprint—remains blocked by the DME moratorium, leaving the West Coast operation with high fixed costs and no incremental volume to absorb them.

A Painful Portfolio Pivot

The strategic rationale for selling Diabetes and folding e-commerce into a JV is to focus on Sleep, Respiratory, and core HME—the businesses with the strongest value proposition and the clearest path to scale. Suzanne framed it as the completion of a two-year pruning process. “This quarter is the completion of that strategy. All of them are good businesses... but with the looming threats out there of competitive bid of having to invest to grow, we thought it would be better to shrink down to our core and build from there.” — Suzanne Foster, Chief Executive Officer · 2026-08-04 The Diabetes health divestiture comes at a price: $100M of EBITDA walks out the door, including $60M of stranded corporate overhead. The company expects to eliminate half of that within a year, but the remaining legacy cost will weigh on margins until 2027. The portfolio actions also include winding down certain Wellness-at-Home product lines, which carry a one-time $15M headwind in H2. As Jason put it, "We have already started shutting down certain sales channels that produce new patient volumes," but servicing the existing census will keep costs elevated for a few quarters. “So the way to think about this as $1 of revenue comes out for these product lines, we drop off about 35% of that revenue. So significantly lower margins than the rest of our business.” — Jason Clemens, Chief Financial Officer · 2026-08-04

Manufacturer Maelstrom

The most shocking item was the sudden price increase from a major manufacturer, effective July 1, with no prior warning. Suzanne acknowledged the unusualness: "It was literally a bit of a surprise to us on June 30." The company is negotiating and may be able to find offsets in product mix or supplier changes, but they've booked the full $30M impact into guidance. This is a reminder that manufacturer leverage still looms over the HME channel, and it underscores how the cost basis is being squeezed from multiple directions. AdaptHealth is now a smaller, more focused company trying to grow its way out of a cost crisis. The portfolio actions are coherent—but they are also painful, and the market is pricing in a long road to recovery. The tapes agree: the stock is down 54% in three months, and the fundamentals are deteriorating faster than expected. Whether the capitated bet eventually pays off depends on the operational fixes Suzanne says are underway. As she told investors, "These growing pains will make us a stronger, more efficient company." The market, for now, is not convinced. For the rest of 2026, watch three things: the speed of West Coast margin recovery, the pace of stranded-cost removal, and whether the manufacturer negotiation lands closer to zero. Each is a swing factor of $30–40 million—enough to decide whether this becomes a turnaround story or a cautionary tale.